On January 4, 2018 IntelGenx Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company" or "IntelGenx") reported that its President and Chief Executive Officer, Dr. Horst Zerbe, is scheduled to present an overview of the Company’s business at the 10 th Annual Biotech Showcase conference on Tuesday, January 9 at 9:00 a.m. Pacific Time at the Hilton San Francisco Union Square Hotel (Press release, IntelGenx, JAN 3, 2018, View Source [SID1234522909]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast live and archived for 90 days on the Company’s website, at www.intelgenx.com , under "Investors".

Andre Godin , Executive Vice President and Chief Financial Officer, and Dr. Dana Matzen , Vice President Business and Corporate Development, from IntelGenx will also be available for one-on-one meetings in San Francisco from January 8 through 10 . To arrange an investor meeting with IntelGenx , please contact Stephen Kilmer ( [email protected] ) and to arrange a business development meeting please contact Dr. Laëtitia Rodes ( [email protected] ) .

On January 3, 2018 Merck (NYSE:MRK), known as MSD outside the United States and Canada, reported that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories, are scheduled to participate at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 8, 2018 at 4:30 p.m. PST (7:30 p.m. EST) (Press release, Merck & Co, JAN 3, 2018, View Source [SID1234522854]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Investors, analysts, members of the media and the general public are invited to listen to a live audio webcast of the presentation at View Source

On January 3, 2018 Foundation Medicine reported that Troy Cox, chief executive officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 3:30 p.m. PST in San Francisco (Press release, Foundation Medicine, JAN 3, 2018, View Source [SID1234522851]). Additionally, Troy Cox will participate in a panel discussion focused on the Food & Drug Administration and Centers for Medicare and Medicaid Services Parallel Review process on Monday, January 8, 2018 at 5:15 p.m. PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Live, listen-only webcasts of these presentations can be accessed by visiting the investors section of the Foundation Medicine website at investors.foundationmedicine.com. A replay of the webcasts will be available shortly after the conclusion of the presentation and archived on the company’s website for two weeks following the presentations.

On January 3, 2018 Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ("Diffusion" or "the Company"), a clinical-stage biotechnology company focused on extending the life expectancy of cancer patients, reported that David Kalergis, Chairman and Chief Executive Officer, will present an overview of the Company and recent advancements of its lead product candidate, trans sodium crocetinate (TSC), at the 10th Annual Biotech Showcase Conference to be held on January 8–10, 2018 at the Hilton San Francisco Union Square Hotel (Press release, Diffusion Pharmaceuticals, JAN 3, 2018, View Source [SID1234522840]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Mr. Kalergis is scheduled to present on Monday, January 8, 2018 at 2:30 p.m. Pacific time.

The presentation will be webcast live and available only during the time of the Company’s live presentation. To access the live webcast, investors may visit the investor relations section of Diffusion Pharmaceuticals website at www.diffusionpharma.com.

On January 3, 2018 Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) reported that management will present at the J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 12:30 p.m. ET (9:30 a.m. PT) (Press release, Vertex Pharmaceuticals, JAN 3, 2018, View Source [SID1234522859]). The audio portion of management’s remarks can be accessed live through Vertex’s website, www.vrtx.com in the "Investors" section under the "News and Events" page.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, the company announced today that it will report its fourth-quarter and full-year 2017 financial results on Wednesday, January 31 after the markets close. In conjunction with the announcement, management will host a conference call that day at 4:30 p.m. ET. To participate in the conference call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International). The call will also be available as a live and archived webcast on Vertex’s website.